Masao Nakagawa

Masao Nakagawa

Auto-generated profile, based on publicly available information

Masao Nakagawa

Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2019 in Blood
Verified
Journal Article
Open access
PDF file
JZJing-Ping Zhang
Jing-Ping Zhang
ZSZhihui Song
Zhihui Song
HWHong-Bo Wang
Hong-Bo Wang
LLLang Lang
Lang Lang
YYYuan-Zhong Yang
Yuan-Zhong Yang
YYYIBIN YANG
YIBIN YANG
The success of programmed cell death protein 1 (PD-1)/PD-L1-based immunotherapy highlights the critical role played by PD-L1 in cancer progression and reveals an urgent need to develop new approaches to attenuate PD-L1 function by gaining insight into how its expression is controlled. Anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALK+ ALCL) expresses a high level of PD-L1 as a result of the constitutive activation of multiple oncogenic signaling pathways downstream of ALK activity, making it an excellent model in which to define the signaling processes responsible for PD-L1 upregulation in tumor cells. Here, using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 library screening, we sought a comprehensive understanding of the molecular effectors required for PD-L1 regulation in ALK+ ALCL. Indeed, we determined that PD-L1 induction is dependent on the nucleophosmin-ALK oncoprotein activation of STAT3, as well as a signalosome containing GRB2/SOS1, which activates the MEK-ERK and PI3K-AKT signaling pathways. These signaling networks, through STAT3 and the GRB2/SOS1, ultimately induce PD-L1 expression through the action of transcription factors IRF4 and BATF3 on the enhancer region of the PD-L1 gene. IRF4 and BATF3 are essential for PD-L1 upregulation, and IRF4 expression is correlated with PD-L1 levels in primary ALK+ ALCL tissues. Targeting this oncogenic signaling pathway in ALK+ ALCL largely inhibited the ability of PD-L1-mediated tumor immune escape when cocultured with PD-1-positive T cells and natural killer cells. Thus, our identification of this previously unrecognized regulatory hub not only accelerates our understanding of the molecular circuitry that drives tumor immune escape but also provides novel opportunities to improve immunotherapeutic intervention strategies.

10 March 2022 in Blood
Verified
Journal Article
Open access
PDF file
TITakashi Ishio
Takashi Ishio
SKSarvesh Kumar
Sarvesh Kumar
JSJoji Shimono
Joji Shimono
ADAnusara Daenthanasanmak
Anusara Daenthanasanmak
SDSigrid Dubois
Sigrid Dubois
MNMasao Nakagawa
Masao Nakagawa
Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis with current therapy. Here we report genome-wide CRISPR-Cas9 screening of ATLL models, which identified CDK6, CCND2, BATF3, JUNB, STAT3, and IL10RB as genes that are essential for the proliferation and/or survival of ATLL cells. As a single agent, the CDK6 inhibitor palbociclib induced cell cycle arrest and apoptosis in ATLL models with wild-type TP53. ATLL models that had inactivated TP53 genetically were relatively resistant to palbociclib owing to compensatory CDK2 activity, and this resistance could be reversed by APR-246, a small molecule activator of mutant TP53. The CRISPR-Cas9 screen further highlighted the dependence of ATLL cells on mTORC1 signaling. Treatment of ATLL cells with palbociclib in combination with mTORC1 inhibitors was synergistically toxic irrespective of the TP53 status. This work defines CDK6 as a novel therapeutic target for ATLL and supports the clinical evaluation of palbociclib in combination with mTORC1 inhibitors in this recalcitrant malignancy.

28 April 2005 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MNMasao Nakagawa
Masao Nakagawa
YKYoshihiro Kameoka
Yoshihiro Kameoka
Ritsuro SuzukiRitsuro Suzuki
Ritsuro Suzuki
Falini et al. (Jan. 20 issue)1 report an abnormal cytoplasmic localization of nucleophosmin (NPM) in 35 percent of specimens from patients with acute myelogenous leukemia. In these patients the NPM gene was mutated, which resulted in a frame shift. The authors state that tryptophan residues at positions 288 and 290 of NPM played a role in the cytoplasmic translocation of NPM. However, these residues are responsible only for nucleolar localization of NPM, not for cytoplasmic localization.2 We found a motif containing leucine-valine residues, known as the nuclear-export-signal (NES) motif, in the C-terminal of mutated NPMs A to F in Figure 4B of the article ( Figure 1 ). The typical nuclear-export signal consists of a short stretch of hydrophobic amino acids (predominantly leucines) and fits the consensus sequence Lx(1-3)Lx(2-3)LxL (with x indicating any residues).3 NES-containing molecules are recognized by nuclear export receptor CRM1 and are then exported to cytoplasm.4 We believe that the NES generated by the mutation of the NPM gene is important for cytoplasmic localization of NPM and tumorigenesis in acute myelogenous leukemia.

3 November 2022 in Blood
Verified
Journal Article
Open access
PDF file
MCMasahiro Chiba
Masahiro Chiba
JSJoji Shimono
Joji Shimono
TITakashi Ishio
Takashi Ishio
NTNorio Takei
Norio Takei
KKKohei Kasahara
Kohei Kasahara
MNMasao Nakagawa
Masao Nakagawa
Adult T-cell leukemia/lymphoma (ATLL) is one of the aggressive peripheral T-cell neoplasms with a poor prognosis. Accumulating evidence demonstrates that escape from adaptive immunity is a hallmark of ATLL pathogenesis. However, the mechanisms by which ATLL cells evade natural killer (NK)-cell–mediated immunity have been poorly understood. Here we show that CD48 expression in ATLL cells determines the sensitivity for NK-cell–mediated cytotoxicity against ATLL cells. We performed unbiased genome-wide clustered regularly interspaced short palindromic repeat (CRISPR) screening using 2 ATLL-derived cell lines and discovered CD48 as one of the best-enriched genes whose knockout conferred resistance to YT1–NK cell line-mediated cytotoxicity. The ability of CD48-knockout ATLL cells to evade NK-cell effector function was confirmed using human primary NK cells with reduced interferon-γ (IFNγ) induction and degranulation. We found that primary ATLL cells had reduced CD48 expression along with disease progression. Furthermore, other subgroups among aggressive peripheral T-cell lymphomas (PTCLs) also expressed lower concentrations of CD48 than normal T cells, suggesting that CD48 is a key molecule in malignant T-cell evasion of NK-cell surveillance. Thus, this study demonstrates that CD48 expression is likely critical for malignant T-cell lymphoma cell regulation of NK-cell–mediated immunity and provides a rationale for future evaluation of CD48 as a molecular biomarker in NK-cell–associated immunotherapies.

1 December 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
WWWei Wei
Wei Wei
ZSZhihui Song
Zhihui Song
MCMasahiro Chiba
Masahiro Chiba
WWWenjun Wu
Wenjun Wu
SJSubin Jeong
Subin Jeong
YYYIBIN YANG
YIBIN YANG

30 March 2006 in Leukemia
Verified
Journal Article
Open access
PDF file
MNM Nakagawa
M Nakagawa
MSM Seto
M Seto
YHYoshitaka Hosokawa
Yoshitaka Hosokawa
At least three recurrent chromosomal translocations, t(11;18)(q21;q21), t(1;14)(p22;q32), t(14;18)(q32;q21), involving the API2-MALT1 fusion protein, BCL10 and MALT1, have been implicated in the pathogenesis of mucosa-associated lymphoid tissue (MALT) lymphoma. Several lines of evidence indicated that both BCL10 and MALT1 are required for nuclear factor kappa B (NF-κB) activation by antigen receptor stimulation in lymphocytes, and API2-MALT1 can bypass this BCL10/MALT1 signaling pathway. Nuclear factor kappa B activation may contribute to antiapoptotic effect through NF-κB-mediated upregulation of apoptotic inhibitor genes. We recently demonstrated that API2-MALT1 can induce transactivation of the API2 gene through NF-κB activation, thus highlighting a positive feedback-loop mechanism of self-activation by upregulating its own expression in t(11;18) MALT lymphomas. We also demonstrated that API2-MALT1 possesses an antiapoptotic effect, in part, through its direct interaction with apoptotic regulators. These findings therefore led us to hypothesize that the antiapoptotic effect by API2-MALT1 may be mediated by its interaction with apoptotic regulators, on the one hand, and by NF-κB-mediated upregulation of apoptotic inhibitor genes on the other. We also found that BCL10 and MALT1 are shuttling between nucleus and cytoplasm, and that MALT1 can regulate the subcellular location of BCL10.